Ekhtiari Seper, Phillips Mark, Dhillon Dalraj, Shahabinezhad Ali, Bhandari Mohit
Department of Orthopaedic Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Department of Surgery, McMaster University, Hamilton, Canada.
J Hand Surg Glob Online. 2024 Jul 15;6(5):659-664. doi: 10.1016/j.jhsg.2024.06.006. eCollection 2024 Sep.
The objective of this study was to perform a cost-utility analysis comparing open carpal tunnel release (OCTR), endoscopic carpal tunnel release (ECTR), and carpal tunnel release with ultrasound (CTR-US) guidance. The aim of this study was to determine whether one of the three approaches was dominant from a societal perspective in terms of cost-utility, in order to help inform policy and treatment decision making going forward.
This study was performed using a decision tree model, with three potential treatment decisions (OCTR, ECTR, and CTR-US). A cost-utility analysis was performed, using the incremental cost-effectiveness ratio. The willingness-to-pay threshold was set at $50,000/quality-adjusted life year (QALY) as per previous literature.
The total payer episode costs for OCTR, ECTR, and CTR-US were $4,324, $4,978, and $3,249, respectively. The cost of time off work for each procedure was $4,376.14, $3,650.24, and $622.20, respectively. The overall QALYs gained from each procedure were 0.42, 0.42, and 0.43, respectively (the maximum possible being 0.5 for a 6-month period). Compared with OCTR, ECTR and CTR-US were both less costly from a societal perspective (-$71.90 and -$4,828.94, respectively) and associated with greater QALYs gained (+0.0004 and +0.0143, respectively).
Overall, the key finding of this study is that, from a societal perspective, CTR-US is less costly and provides greater QALY improvement when compared with OCTR and ECTR, and thus, CTR-US is considered a dominant intervention over both OCTR and ECTR.
TYPE OF STUDY/LEVEL OF EVIDENCE: Economic and decision analysis; IIb.
本研究的目的是进行成本效用分析,比较开放式腕管松解术(OCTR)、内镜下腕管松解术(ECTR)和超声引导下腕管松解术(CTR-US)。本研究的目的是确定从社会角度来看,这三种方法中的一种在成本效用方面是否占主导地位,以便为未来的政策和治疗决策提供参考。
本研究使用决策树模型进行,有三种潜在的治疗决策(OCTR、ECTR和CTR-US)。使用增量成本效益比进行成本效用分析。根据先前的文献,支付意愿阈值设定为50,000美元/质量调整生命年(QALY)。
OCTR、ECTR和CTR-US的总支付者事件成本分别为4,324美元、4,978美元和3,249美元。每个手术的误工成本分别为4,376.14美元、3,650.24美元和622.20美元。每个手术获得的总体QALY分别为0.42、0.42和0.43(6个月期间的最大值为0.5)。与OCTR相比,从社会角度来看,ECTR和CTR-US的成本都更低(分别为-71.90美元和-4,828.94美元),并且获得的QALY更高(分别为+0.0004和+0.0143)。
总体而言,本研究的主要发现是,从社会角度来看,与OCTR和ECTR相比,CTR-US成本更低,QALY改善更大,因此,CTR-US被认为是优于OCTR和ECTR的主要干预措施。
研究类型/证据水平:经济与决策分析;IIb级。